阳光诺和签署STC008注射液《技术开发合同》

Core Viewpoint - The company has entered into a cooperation agreement with Zhejiang Xinghao Holdings to jointly develop the STC008 injection project, which is expected to positively impact future performance and enhance profitability [1] Group 1: Financial Terms - The company will receive an initial payment of RMB 50 million and subsequent milestone payments, totaling RMB 500 million (including tax) [1] - The company will also receive an 8% share of the net sales (excluding tax) from the project [1] Group 2: Project Details - STC008 is a self-initiated research and development project aimed at treating cancer cachexia in patients with advanced solid tumors [1] - The project is currently in the Phase I clinical trial stage [1]